IBM Fellows

Introducing IBM Research’s 2019 Fellows

Share this post:

The recognition of IBM Fellows is part of the long history of excellence at IBM.  It is the most prestigious recognition in the IBM technical community and is earned through a distinguished, sustained record of technical achievement and a strong potential for continuing contributions to the growth and stature of IBM.

Please join me in congratulating two IBM Research colleagues on this exceptional achievement – Laxmi Parida and Gustavo Stolovitzy.

Also, congratulations to the entire class of 2019 IBM Fellows, who are named here.  It is an honor to have you as colleagues!

“Staying resolutely focused is the hallmark of a committed scientist, and potentially leads to innovations. But one also must be cognizant of advances from other fields, and open to new perspectives on recalcitrant problems.”

– Laxmi Parida

Laxmi Parida

Laxmi Parida

Laxmi is a world-renowned expert in computational genomics whose breakthrough contributions to algorithms have benefited human health and society. She was instrumental in the core engine’s design and accuracy for the Watson for Genomics offering in precision oncology. Laxmi pioneered the Genographic Project’s reconstruction of deep ancestry from the recombining genome – a breakthrough with far-reaching consequences and demonstrated success in plant and tumor genomics. In the Cacao Project, her work was instrumental to marker-assisted breeding that enabled IBM’s client to diversify the crop and expand its supply chain into additional regions to secure against fungal pest. Laxmi’s melding of AI with genomics of neurological diseases has redefined classical epidemiology in Alzheimer’s and Parkinson’s diseases for discovery of causal biomarkers. She has also made fundamental contributions to pattern discovery in bioinformatics and pioneered algebraic topology in genomics, with success in microbiomes and population admixture.

 “I am a committed proponent of open science, especially in biomedicine, where speed in research may result in saving patients’ lives.”

 – Gustavo Stolovitzky

Gustavo Stolovitzky

Gustavo Stolovitzky

Gustavo is a pioneer in the area of crowdsourcing and its application to computational biology, which helped achieve breakthroughs in network biology and cancer genomics. He created the DREAM Challenges, engaging more than 15,000 researchers to address a range of medical challenges – predicting if cancer cells will respond to a drug, predicting the speed of progression in patients with amyotrophic lateral sclerosis (ALS, or Lou Gehrig’s disease), predicting the survival of prostate cancer patients, and many other challenges. In 2017, Gustavo led the Digital Mammography DREAM Challenge in the IBM cloud to crowdsource the development of AI algorithms to interpret mammograms for breast cancer screening. Previously, he established the nanobiotechnology program in IBM Research, producing innovations on DNA sequencing and precision medicine at the interface between silicon technology and molecular biology.

Director of IBM Research

More IBM Fellows stories

Dark Matter Matters: AI Makes DNA Dark Matter Useful

What is the minimal description that captures a space? Asking a mathematician’s basic question of a  biological dataset reveals interesting answers about biology itself. This summarizes our underlying approach to subtyping hematological cancer. Disease subtyping is a central tenet of precision medicine, and is the challenging task of identifying and classifying patients with similar presentations […]

Continue reading

Helping to Untangle Cancer Drug Resistance with Data

Why do targeted cancer therapies often fail? We have acquired so much more understanding about cancer in the last fifty years than in the last five thousand years. Approaches to patient treatments have dramatically changed, and statistics show significant improvement in patient response and outcomes to therapy in the last half a century [1]. Yet […]

Continue reading

Novel AI tools to accelerate cancer research

At the 18th European Conference on Computational Biology and the 27th Conference on Intelligent Systems for Molecular Biology, IBM will present significant, novel research that led to the implementation of three machine learning solutions aimed at accelerating and guiding cancer research.

Continue reading